{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:33:57Z","timestamp":1777541637396,"version":"3.51.4"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.prrv.2022.10.001","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T12:23:46Z","timestamp":1664972626000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cystic Fibrosis-Related Diabetes: Clinical approach and knowledge gaps"],"prefix":"10.1016","volume":"46","author":[{"given":"Bernadette J.","family":"Prentice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn J.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad\u00e8le","family":"Coriati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Rusnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamizan","family":"Kherani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Senior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihab","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9mi","family":"Rabasa-Lhoret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.prrv.2022.10.001_b0005","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.lpm.2017.04.012","article-title":"The changing epidemiology and demography of cystic fibrosis","volume":"46","author":"Stephenson","year":"2017","journal-title":"La Presse M\u00e9dicale"},{"issue":"1","key":"10.1016\/j.prrv.2022.10.001_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/157339910790442600","article-title":"Cystic fibrosis related diabetes mellitus - diagnostic and management challenges","volume":"6","author":"Lek","year":"2010","journal-title":"Curr Diabetes Rev"},{"issue":"Suppl 27","key":"10.1016\/j.prrv.2022.10.001_b0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/pedi.12732","article-title":"ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents","volume":"19","author":"Moran","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.prrv.2022.10.001_b0020","unstructured":"Canada CF. Cystic Fibrosis Canada 2020 Annual Data Report. 2020."},{"issue":"8","key":"10.1016\/j.prrv.2022.10.001_b0025","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0030","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2022.10.001_b0035","doi-asserted-by":"crossref","first-page":"702823","DOI":"10.3389\/fendo.2021.702823","article-title":"The potential causes of cystic fibrosis-related diabetes","volume":"12","author":"Coderre","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.prrv.2022.10.001_b0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jcf.2020.11.022","article-title":"Influence of pre-diabetic and pancreatic exocrine states on pulmonary and nutritional status in adults with Cystic Fibrosis","volume":"20","author":"Potter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2022.10.001_b0045","doi-asserted-by":"crossref","unstructured":"Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-708. Epub 2010\/12\/01. 10.2337\/dc10-1768. PubMed PMID: 21115772; PubMed Central PMCID: PMCPMC2992215.","DOI":"10.2337\/dc10-1768"},{"issue":"4","key":"10.1016\/j.prrv.2022.10.001_b0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/pedi.12094","article-title":"Importance of screening with oral glucose tolerance test for early diagnosis of cystic fibrosis-related diabetes mellitus: early diagnosis of cystic fibrosis-related diabetes","volume":"15","author":"Noronha","year":"2014","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"10.1016\/j.prrv.2022.10.001_b0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/MOP.0000000000000251","article-title":"Advances in the detection and management of cystic fibrosis related diabetes","volume":"27","author":"Hameed","year":"2015","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.prrv.2022.10.001_b0060","doi-asserted-by":"crossref","unstructured":"Terliesner N, Vogel M, Steighardt A, Gausche R, Henn C, Hentschel J, et al. Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function. J Pediatr Endocrinol Metab. 2017;30(8):815-21. Epub 2017\/03\/01. 10.1515\/jpem-2017-0005. PubMed PMID: 28245190.","DOI":"10.1515\/jpem-2017-0005"},{"issue":"8","key":"10.1016\/j.prrv.2022.10.001_b0065","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/dc16-0020","article-title":"Does \u03b2-Cell autoimmunity play a role in cystic fibrosis-related diabetes? Analysis Based on the German\/Austrian Diabetes Patienten Verlaufsdokumentation Registry","volume":"39","author":"Konrad","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.prrv.2022.10.001_b0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2337\/dc12-0807","article-title":"Comparison of cystic fibrosis-related diabetes with type 1 diabetes based on a German\/Austrian Pediatric Diabetes Registry","volume":"36","author":"Konrad","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0075","doi-asserted-by":"crossref","first-page":"e00208","DOI":"10.1002\/edm2.208","article-title":"Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations","volume":"4","author":"Merjaneh","year":"2021","journal-title":"Endocrino Diabet & Metabol"},{"issue":"4","key":"10.1016\/j.prrv.2022.10.001_b0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2019.01.009","article-title":"The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity","volume":"18","author":"Colomba","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.prrv.2022.10.001_b0085","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/diab.43.8.1020","article-title":"Insulin sensitivity in cystic fibrosis","volume":"43","author":"Moran","year":"1994","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.prrv.2022.10.001_b0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jcf.2016.04.004","article-title":"Variation of glucose tolerance in adult patients with cystic fibrosis: What is the potential contribution of insulin sensitivity?","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.prrv.2022.10.001_b0095","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00125-009-1436-2","article-title":"A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis","volume":"52","author":"Blackman","year":"2009","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.prrv.2022.10.001_b0100","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1515\/jpem-2019-0484","article-title":"Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment","volume":"33","author":"Alves","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.prrv.2022.10.001_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.prrv.2022.10.001_b0115","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jcf.2009.08.007","article-title":"Validation of insulin secretion indices in cystic fibrosis patients","volume":"8","author":"Hammana","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.prrv.2022.10.001_b0120","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jcf.2007.02.005","article-title":"Increased glucose excursion in cystic fibrosis and its association with a worse clinical status","volume":"6","author":"Costa","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.prrv.2022.10.001_b0125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.prrv.2022.10.001_b0130","article-title":"In situ analysis reveals that CFTR is expressed in only a small minority of beta-cells in normal adult human pancreas","author":"White","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.prrv.2022.10.001_b0135","doi-asserted-by":"crossref","unstructured":"Kelsey R, Manderson Koivula FN, McClenaghan NH, Kelly C. Cystic fibrosis-related diabetes: pathophysiology and therapeutic challenges. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419851770. Epub 2019\/06\/14. 10.1177\/1179551419851770. PubMed PMID: 31191067; PubMed Central PMCID: PMCPMC6539575.","DOI":"10.1177\/1179551419851770"},{"issue":"3","key":"10.1016\/j.prrv.2022.10.001_b0140","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0046-8177(84)80191-4","article-title":"Endocrine pancreas in cystic fibrosis: An immunohistochemical study","volume":"15","author":"Iannucci","year":"1984","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00718598","article-title":"Cystic fibrosis associated islet changes may provide a basis for diabetes: An immunocytochemical and morphometrical study","volume":"414","author":"L\u00f6hr","year":"1989","journal-title":"Vichows Archiv A Pathol Anat"},{"issue":"1","key":"10.1016\/j.prrv.2022.10.001_b0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18388\/abp.2014_853","article-title":"Role of pro-inflammatory cytokines of pancreatic islets and prospects of elaboration of new methods for the diabetes treatment","volume":"62","author":"Cie\u015blak","year":"2015","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.prrv.2022.10.001_b0155","doi-asserted-by":"crossref","unstructured":"Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med. 2002;19(3):221-6. Epub 2002\/04\/20. 10.1046\/j.1464-5491.2002.00666.x. PubMed PMID: 11963922.","DOI":"10.1046\/j.1464-5491.2002.00666.x"},{"key":"10.1016\/j.prrv.2022.10.001_b0160","article-title":"Insulinogenic index and early phase insulin secretion predict increased risk of worsening glucose tolerance and of cystic fibrosis-related diabetes","author":"Potter","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.prrv.2022.10.001_b0165","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pedi.12700","article-title":"Beta-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose >\/=155 mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"10.1016\/j.prrv.2022.10.001_b0170","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jdiacomp.2014.06.012","article-title":"Cystic fibrosis related diabetes\u2014a new perspective on the optimal management of postprandial glycemia","volume":"28","author":"Perano","year":"2014","journal-title":"J Diabetes Complications"},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4239\/wjd.v6.i2.296","article-title":"Prediabetes diagnosis and treatment: a review","volume":"6","author":"Bansal","year":"2015","journal-title":"World J Diabetes"},{"issue":"5","key":"10.1016\/j.prrv.2022.10.001_b0180","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ppul.25207","article-title":"Trajectories of oral glucose tolerance testing in cystic fibrosis","volume":"56","author":"Patel","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.prrv.2022.10.001_b0185","doi-asserted-by":"crossref","first-page":"e112578","DOI":"10.1371\/journal.pone.0112578","article-title":"High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study","volume":"9","author":"Scheuing","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.prrv.2022.10.001_b0190","doi-asserted-by":"crossref","unstructured":"Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr. 2008;152(4):540-5, 5.e1. Epub 2008\/03\/19. 10.1016\/j.jpeds.2007.09.025. PubMed PMID: 18346512.","DOI":"10.1016\/j.jpeds.2007.09.025"},{"issue":"10","key":"10.1016\/j.prrv.2022.10.001_b0195","doi-asserted-by":"crossref","first-page":"e3901","DOI":"10.1210\/clinem\/dgab384","article-title":"Combined indeterminate and impaired glucose tolerance is a novel group at high risk of cystic fibrosis-related diabetes","volume":"106","author":"Potter","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.prrv.2022.10.001_b0200","doi-asserted-by":"crossref","unstructured":"Colomba J, Netedu SR, Lehoux-Dubois C, Coriati A, Boudreau V, Tremblay F, et al. Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis. PLoS One 2019;14(7):e0219855. Epub 2019\/07\/19. 10.1371\/journal.pone.0219855. PubMed PMID: 31318914; PubMed Central PMCID: PMCPMC6638946 No other authors have any conflicts of interest to disclose. This does not alter our adherence to PLOS ONE policies on sharing data and materials.","DOI":"10.1371\/journal.pone.0219855"},{"issue":"5","key":"10.1016\/j.prrv.2022.10.001_b0205","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1210\/jc.2013-2756","article-title":"Impact of sex on insulin secretion in cystic fibrosis","volume":"99","author":"Coriati","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"10.1016\/j.prrv.2022.10.001_b0210","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/BF01957574","article-title":"Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis","volume":"151","author":"Lanng","year":"1992","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.prrv.2022.10.001_b0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcf.2015.03.001","article-title":"Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET)","volume":"15","author":"Coriati","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2022.10.001_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.673539","article-title":"Diabetes and prediabetes in children with cystic fibrosis: a systematic review of the literature and recommendations of the Italian society for pediatric endocrinology and diabetes (ISPED)","volume":"12","author":"Mozzillo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.prrv.2022.10.001_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246897","article-title":"Impact of 1h oral glucose tolerance test on the clinical status of adult cystic fibrosis patients over a 4-year period","volume":"16","author":"Boudreau","year":"2021","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.prrv.2022.10.001_b0230","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/ppul.21127","article-title":"Growth in children with cystic fibrosis-related diabetes","volume":"44","author":"Cheung","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2022.10.001_b0235","unstructured":"Verge CF. Cystic Fibrosis - Insulin Deficiency, Early Action (CF-IDEA). clinicaltrialsgov. 2010;NCT01100892."},{"issue":"Suppl 20","key":"10.1016\/j.prrv.2022.10.001_b0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/pedi.12178","article-title":"ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents","volume":"15","author":"Moran","year":"2014","journal-title":"Pediatr Diabetes"},{"issue":"10","key":"10.1016\/j.prrv.2022.10.001_b0245","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/08870446.2016.1183008","article-title":"How patients' representations of cystic fibrosis-related diabetes inform their health behaviours","volume":"31","author":"Sylvain","year":"2016","journal-title":"Psychol Health"},{"issue":"5","key":"10.1016\/j.prrv.2022.10.001_b0250","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcjd.2016.08.221","article-title":"Screening for cystic fibrosis-related diabetes: matching pathophysiology and addressing current challenges","volume":"40","author":"Boudreau","year":"2016","journal-title":"Can J Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.prrv.2022.10.001_b0255","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcjd.2017.10.003","article-title":"Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome","volume":"42","author":"Punthakee","year":"2018","journal-title":"Can J Diabetes"},{"issue":"6 Pt 1","key":"10.1016\/j.prrv.2022.10.001_b0260","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.diabet.2008.05.010","article-title":"No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes","volume":"34","author":"Godbout","year":"2008","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.prrv.2022.10.001_b0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcjd.2018.04.008","article-title":"Cystic Fibrosis-related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels","volume":"43","author":"Gilmour","year":"2019","journal-title":"Can J Diabetes"},{"issue":"3","key":"10.1016\/j.prrv.2022.10.001_b0270","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jcjd.2018.11.005","article-title":"Validation of a stepwise approach using glycated hemoglobin levels to reduce the number of required oral glucose tolerance tests to screen for cystic fibrosis-related diabetes in adults","volume":"43","author":"Boudreau","year":"2019","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.prrv.2022.10.001_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjd.2021.03.005","article-title":"Glycated hemoglobin as a first-line screening test for cystic fibrosis-related diabetes and impaired glucose tolerance in children with cystic fibrosis: a validation study","author":"Racine","year":"2021","journal-title":"Can J Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.prrv.2022.10.001_b0280","first-page":"S17","article-title":"Standards of medical care in diabetes-2022","volume":"45","author":"Classification and Diagnosis of Diabetes","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.prrv.2022.10.001_b0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/jpem-2016-0184","article-title":"Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?","volume":"30","author":"Mainguy","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.prrv.2022.10.001_b0290","doi-asserted-by":"crossref","first-page":"1527932","DOI":"10.1155\/2016\/1527932","article-title":"Glucose >200 mg\/dL during continuous glucose monitoring identifies adult patients at risk for development of cystic fibrosis related diabetes","volume":"2016","author":"Taylor-Cousar","year":"2016","journal-title":"J Diabetes Res"},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0295","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcf.2019.05.005","article-title":"Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis","volume":"19","author":"Prentice","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.prrv.2022.10.001_b0300","first-page":"45","article-title":"Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients","volume":"65","author":"Clemente Le\u00f3n","year":"2018","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)."},{"issue":"6","key":"10.1016\/j.prrv.2022.10.001_b0305","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc08-1925","article-title":"Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study","volume":"32","author":"O'Riordan","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.prrv.2022.10.001_b0310","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.2337\/diacare.26.6.1940-a","article-title":"Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis","volume":"26","author":"Dobson","year":"2003","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.prrv.2022.10.001_b0315","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2021.01.002","article-title":"Abnormal glucose tolerance and lung function in children with cystic fibrosis. Comparing oral glucose tolerance test and continuous glucose monitoring","volume":"20","author":"Elidottir","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2022.10.001_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.659728","article-title":"continuous glucose monitoring as a valuable tool in the early detection of diabetes related to cystic fibrosis","volume":"9","author":"Gojsina","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.prrv.2022.10.001_b0325","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1183\/16000617.0293-2020","article-title":"Cystic fibrosis-related diabetes and lung disease: an update","volume":"30","author":"Prentice","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.prrv.2022.10.001_b0330","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s00125-021-05423-5","article-title":"Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis","volume":"64","author":"Bonhoure","year":"2021","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.prrv.2022.10.001_b0335","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1139\/apnm-2013-0022","article-title":"Diagnosis of cystic fibrosis-related glucose abnormalities: Can we shorten the standard oral glucose tolerance test?","volume":"38","author":"Coriati","year":"2013","journal-title":"Appl Physiol Nutr Metab"},{"issue":"3","key":"10.1016\/j.prrv.2022.10.001_b0340","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diabet.2011.01.002","article-title":"How can we measure insulin sensitivity\/resistance?","volume":"37","author":"Antuna-Puente","year":"2011","journal-title":"Diabetes Metab."},{"issue":"Suppl 2","key":"10.1016\/j.prrv.2022.10.001_b0345","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cyst Fibros."},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0350","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1249\/MSS.0000000000001104","article-title":"Combined exercise training improves glycemic control in adult with cystic fibrosis","volume":"49","author":"Beaudoin","year":"2017","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.prrv.2022.10.001_b0355","doi-asserted-by":"crossref","unstructured":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-713. PubMed PMID: 9732337; PubMed Central PMCID: PMCPMC28659.","DOI":"10.1136\/bmj.317.7160.703"},{"issue":"5","key":"10.1016\/j.prrv.2022.10.001_b0360","doi-asserted-by":"crossref","first-page":"E886","DOI":"10.1152\/ajpendo.00608.2020","article-title":"The promising future of insulin therapy in diabetes mellitus","volume":"320","author":"Cheng","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0365","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ajcn.81.2.421","article-title":"Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis","volume":"81","author":"Rafii","year":"2005","journal-title":"Am J Clin Nutr."},{"issue":"10","key":"10.1016\/j.prrv.2022.10.001_b0370","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"7-8","key":"10.1016\/j.prrv.2022.10.001_b0375","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1515\/jpem.2011.050","article-title":"Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study","volume":"24","author":"Kolouskova","year":"2011","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0380","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000110206","article-title":"Long-term effect of insulin treatment in cystic fibrosis-related diabetes","volume":"76","author":"Mohan","year":"2008","journal-title":"Respiration"},{"issue":"8","key":"10.1016\/j.prrv.2022.10.001_b0385","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1651-2227.1994.tb13156.x","article-title":"Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections","volume":"83","author":"Lanng","year":"1994","journal-title":"Acta Paediatr"},{"issue":"1","key":"10.1016\/j.prrv.2022.10.001_b0390","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/pedi.12158","article-title":"Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes?","volume":"16","author":"Scheuing","year":"2015","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.prrv.2022.10.001_b0395","doi-asserted-by":"crossref","first-page":"e14854","DOI":"10.1111\/dme.14854","article-title":"Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials","author":"Elbalshy","year":"2022","journal-title":"Diabet Med"},{"issue":"12","key":"10.1016\/j.prrv.2022.10.001_b0400","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S2213-8587(21)00290-4","article-title":"Defining type 2 diabetes remission: KISS goodbye to confusion?","volume":"9","author":"Taheri","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.prrv.2022.10.001_b0405","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6823-6-4","article-title":"Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study","volume":"6","author":"Onady","year":"2006","journal-title":"BMC Endocr Disord."},{"key":"10.1016\/j.prrv.2022.10.001_b0410","doi-asserted-by":"crossref","unstructured":"Onady GM, Stolfi A. Drug treatments for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev. 2020;10(10):Cd004730. Epub 2020\/10\/20. 10.1002\/14651858.CD004730.pub5. PubMed PMID: 33075159; PubMed Central PMCID: PMCPMC8094754 these Guidelines published in Diabetes Care in December 2010. He wrote the management component of that manuscript. This position has in no way influenced this subsequent and more recent review. In fact, this review puts into question the recommendations made in that earlier publication. He also serves on the Cystic Fibrosis Foundation's Center Committee, whose work is totally devoted to the clinical accreditation of CF Centers across the USA, and does not involve details as to the subject matter involved in this Cochrane Review. He has received travel and accomodation expenses from the Cystic Fibrosis Foundation. Adrienne Stolfi declares no known potential conflict of interest.","DOI":"10.1002\/14651858.CD004730.pub5"},{"issue":"9","key":"10.1016\/j.prrv.2022.10.001_b0415","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","article-title":"Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"10.1016\/j.prrv.2022.10.001_b0420","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2337\/dc13-1210","article-title":"Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials","volume":"38","author":"Jensen","year":"2015","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.prrv.2022.10.001_b0425","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/1753-0407.13078","article-title":"Adjunct therapies in treatment of type 1 diabetes","volume":"12","author":"Goyal","year":"2020","journal-title":"J Diabetes."},{"issue":"1","key":"10.1016\/j.prrv.2022.10.001_b0430","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1080\/07853890.2020.1841281","article-title":"The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection","volume":"53","author":"Brown","year":"2021","journal-title":"Ann Med"},{"key":"10.1016\/j.prrv.2022.10.001_b0435","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14702","article-title":"Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: a systematic review and network meta-analysis","author":"Cao","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.prrv.2022.10.001_b0440","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201808-1501ED","article-title":"Is cystic fibrosis-related diabetes reversible? New data on CFTR potentiation and insulin secretion","volume":"199","author":"Norris","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.prrv.2022.10.001_b0445","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/Ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.prrv.2022.10.001_b0450","first-page":"192","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: The first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J Pediatr Pharmacol Ther"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054222000677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054222000677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:37:29Z","timestamp":1761507449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054222000677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":90,"alternative-id":["S1526054222000677"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2022.10.001","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic Fibrosis-Related Diabetes: Clinical approach and knowledge gaps","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2022.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}